Liquidia Corporation

We are deeply passionate and committed to the discovery, engineering, and development required to bring novel therapies to patients who need them most, and to the healthcare providers who care for them. Our current drive is toward improving the treatment of pulmonary arterial hypertension (PAH).

We will continue to combine our proprietary, innovative PRINT Technology with new and established medications, offering the potential for both better precision and improved clinical outcomes.

News Releases

AUG 11 2022

Liquidia Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Company to host webcast and conference call today at 8:30 a.m. ET MORRISVILLE, N.C. , Aug. 11, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the second quarter ended June 30, 2022 .
AUG 04 2022

Liquidia to Report Second Quarter 2022 Financial Results on August 11, 2022

MORRISVILLE, N.C. , Aug. 04, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its second quarter 2022 financial results on Thursday, August 11, 2022 . The company will host a conference call and webcast at 8:30 a.m.

btn News